ARTICLE | Clinical News
Levicept begins Phase I of fusion protein for chronic pain
September 15, 2017 8:27 PM UTC
Levicept Ltd. (Sandwich, U.K.) began a Phase I trial to evaluate single ascending doses of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of the knee. The double-blind, placebo-controlled, U.K. trial will evaluate safety and neurological assessments, as well as pharmacokinetics.
LEVI-04 is a p75 neurotrophin receptor (p75 NTR) fused with an Fc fragment that partially binds nerve growth factor (NGF) and other neurotrophins...